ClearPoint Neuro (CLPT) Asset Writedowns and Impairment (2020 - 2026)

ClearPoint Neuro has disclosed Asset Writedowns and Impairment across 7 years of filings, most recently posting -$95000.0 for Q1 2026.

• Asset Writedowns and Impairment for Q1 2026 came in at -$95000.0, down 143.78% year-over-year; the trailing twelve-month figure through Mar 2026 was -$291000.0 (down 534.33% YoY), and the FY2025 annual result was $21000.0, up 107.09% from the prior year.
• Asset Writedowns and Impairment came in at -$95000.0 for Q1 2026 at ClearPoint Neuro, up from -$196000.0 in the prior quarter.
• In the past five years, Asset Writedowns and Impairment ranged from a high of $449000.0 in Q3 2023 to a low of -$361000.0 in Q2 2024.
• The 5-year median for Asset Writedowns and Impairment is $13000.0 (2022), against an average of $55071.4.
• Across the five-year window, Asset Writedowns and Impairment plunged 2133.33% in 2022 and surged 1520.0% in 2023, its largest moves.
• ClearPoint Neuro's Asset Writedowns and Impairment stood at -$25000.0 in 2022, then soared by 1520.0% to $355000.0 in 2023, then plunged by 40.56% to $211000.0 in 2024, then plunged by 192.89% to -$196000.0 in 2025, then jumped by 51.53% to -$95000.0 in 2026.
• The last three Asset Writedowns and Impairment figures came in at -$95000.0 (Q1 2026), -$196000.0 (Q4 2025), and $217000.0 (Q1 2025), per Business Quant data.